• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.01% Nasdaq Up0.26%

    Alkermes plc (ALKS)

    74.06 Down 0.20(0.27%) Nov 25, 4:00PM EST
    ProfileGet Profile for:
    Alkermes plc
    Connaught House
    1 Burlington Road
    Dublin, 4
    Ireland - Map
    Phone: 353 1 772 8000
    Website: http://www.alkermes.com

    Index Membership:N/A
    Industry:Drug Delivery
    Full Time Employees:1,300

    Business Summary 

    Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage. The company serves pharmaceutical wholesalers, specialty pharmacies, and specialty distributors directly through its sales force. It has collaboration agreements with Janssen Pharmaceutica, NV; AstraZeneca plc; Acorda Therapeutics, Inc.; and other collaboration partners. Alkermes Public Limited Company was founded in 1987 and is headquartered in Dublin, Ireland.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Alkermes plc

    Corporate Governance 
    Alkermes plc’s ISS Governance QuickScore as of Nov 1, 2015 is 4. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 4; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Richard F. Pops , 53
    Chairman and Chief Exec. Officer
    Mr. Shane Martin Cooke , 53
    Dr. Floyd E. Bloom M.D., 78
    Co-Founder, Director and Member of Audit & Risk Committee
    Mr. James M. Frates , 48
    Chief Financial Officer, Sr. VP and Treasurer
    Ms. Kathryn L. Biberstein , 56
    Chief Compliance Officer, Chief Legal Officer, Sr. VP and Sec.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders